Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays

References

• Brekelmans M, Middeldorp S, Coppens M. Direct factor Xa inhibitor edoxaban: from bench to clinical practice. Expert Rev Hematol. 2015;8:707–702.
   PubMed Web of Science ®Google Scholar
• Poulakos M, Walker JN, Baig U, et al. Edoxaban: a direct oral anticoagulant. Am J Health Syst Pharm. 2017;74:117–129.
   PubMed Web of Science ®Google Scholar
• Reiffel JA, Weitz JI, Reilly PA, et al. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: a cardiac safety research consortium think tank. Am Heart J. 2016;177:74–86.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Finks SW. Edoxaban: how does the newest agent fit into the DOAC landscape? Am J Med. 2017;130:900–906.
   PubMed Web of Science ®Google Scholar
• Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–760.
   Google Scholar
• Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172:315–336.
   PubMed Web of Science ®Google Scholar
• Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743–753.
   PubMed Web of Science ®Google Scholar
• Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2013;75:966–978.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomized, double-blind, ENGAGE AF-TIMI 48 trial. Lancet. 2015;385:2288–2295.
   PubMed Web of Science ®Google Scholar
• Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban. Comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol. 2015;143:241–247.
   PubMed Web of Science ®Google Scholar
• Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38:505–513.
   PubMed Web of Science ®Google Scholar
• Adcock DM, Gosselin RC. The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue. Int J Lab Hematol. 2017;39:37–40.
   PubMed Web of Science ®Google Scholar
• Samama MM, Mendell J, Guinet C, et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012;129:e77–e82.
   PubMed Web of Science ®Google Scholar
• Zahir H, Matsushima N, Halim AB, et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost. 2012;108:166–175.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Chatelain B, Chatelain C, et al. Edoxaban: impact on routine and specific coagulation assays. Thromb Haemost. 2016;115:368–381.
   PubMed Web of Science ®Google Scholar
• Iba T, Emmi M, Hiki M, et al. Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. Int J Hematol. 2016;103:665–672.
   PubMed Web of Science ®Google Scholar
• Sezai A, Osaka S, Yaoita H, et al. Safety of the direct oral anticoagulant edoxaban for atrial fibrillation after cardiac surgery: pilot study. J Atr Fibrillat. 2016;9:1456.
   PubMedGoogle Scholar
• Lindahl TL, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371–378.
   PubMed Web of Science ®Google Scholar
• Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133–139.
   PubMed Web of Science ®Google Scholar
• Hillarp A, Gustafsson KM, Faxälv L, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost. 2014;12:1545–1553.
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Egberg N, Hillarp A, et al. INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples. Thromb Haemost. 2004;91:1223–1231.
   PubMed Web of Science ®Google Scholar
• Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108:191–198.
   PubMed Web of Science ®Google Scholar
• Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542–1549.
   PubMed Web of Science ®Google Scholar
• Hoxha A, Banzato A, Ruffatti A, et al. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev. 2017;16:173–178.
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Arbring K, Wallstedt M, et al. A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs). Ups J Med Sci. 2017;122:171–176.
   PubMed Web of Science ®Google Scholar
• He L, Kochan J, Lin M, et al. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay. Thromb Res. 2017;155:121–127.
   PubMed Web of Science ®Google Scholar